Bladder cancer is a heterogeneous group of tumours with at least 40 histological subgroups.
Patients with localized disease can be cured with surgical resection or radiotherapy, but …

Pathological evaluation of bladder cancer typically reveals great tumour heterogeneity, and
therefore the common observation of urothelial carcinoma exhibiting a wide variety of …

Background Patients with predominant variant histology (VH) of bladder tumors, defined as
involving> 50% of the tumor specimens, are typically excluded from clinical trials, and for …

Stage T1 bladder cancers invade the lamina propria of the bladder and, despite sharing
many of the genetic features of muscle-invasive bladder cancers, are classified as non …

Bladder cancer (BC) is the tenth most commonly diagnosed malignancy worldwide. In
approximately 25% of cases, it presents as a muscle-invasive disease, requiring a radical …

Aim This review article summarizes the current clinical practice guidelines around disease
definitions and risk stratifications, and the treatment of non-muscle-invasive bladder cancer …

Context The optimal treatment of urothelial bladder cancer (UBC) with micropapillary (MP)
variant histology is not clear. Objective To review the current literature on disease …

Purpose: The currently available evidence regarding the prognostic and clinical significance
of each variant histology subtype of urothelial bladder cancer remains scarce. We assessed …

Purpose: Neuroendocrine (NE) bladder carcinoma is a rare and aggressive variant.
Molecular subtyping studies have found that 5% to 15% of muscle-invasive bladder cancer …

The poor 5-year survival rate for bladder cancers is associated with the lack of efficient
diagnostic and treatment techniques. Despite cystoscopy-assisted photomedicine and …